<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05799729</url>
  </required_header>
  <id_info>
    <org_study_id>KetainfusionMAST</org_study_id>
    <nct_id>NCT05799729</nct_id>
  </id_info>
  <brief_title>Effect of Ketamine Infusion on BIS Values</brief_title>
  <official_title>Correlation Between Concentration at the Effector Site of Continuous Infusion of Ketamine (Calculated With DOMINO Pump) and Bispectral Index Values During General Anaesthesia for Breast Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Padova</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Padova</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aim of this trial is to define if Concentration at the effector site (Ce) of Ketamine, during&#xD;
      a continuous infusion and calculated with DOMINO model infusion pump are correlated with&#xD;
      Bispectral Index BIS values during general anaesthesia for breast surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Correlation between Concentration at the effector site (Ce) of Ketamine and Bispectral Index&#xD;
      (BIS) values during general anaesthesia for breast surgery has not been defined yet during a&#xD;
      continuous infusion.&#xD;
&#xD;
      Authors want to analyze this correlation during general anaesthesia conducted using Propofol,&#xD;
      ketamine and remifentanil. All of these drugs will be delivered with Target-Controlled&#xD;
      Infusion pumps (in particular Eleveld for Propofol, Minto for Remifentanil and Domino for&#xD;
      Ketamine).&#xD;
&#xD;
      Ketamine will be observationally set at anaesthesiologist's discretion, but only CeK 0.1,&#xD;
      0.2, 0.4 and 0.6 for at least 30 minutes will be considered for analysis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 30, 2023</start_date>
  <completion_date type="Anticipated">September 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation between Concentration at the effector site of Ketamine and BIS values</measure>
    <time_frame>Data about Drugs concentration and BIS values during general anaesthesia will be collected, in particular BIS and TCI Ketamine values during all the duration of anesthesia, form the start of ketamine infusion until the stop of ketamine infusion (30 min)</time_frame>
    <description>Discover if there is linear correlation between Concentration at the effector site of Ketamine and BIS values during standard general anaesthesia conducted with Propofol, remifenatnil and ketamine delivered with targeted controlled infusion pumps, usually adopted in our Hospital to delivery general anaesthesia</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Anesthesia Brain Monitoring</condition>
  <condition>Ketamine</condition>
  <arm_group>
    <arm_group_label>CeK 0.1</arm_group_label>
    <description>Data about Continuous infusion with Concentration at the effector site of Ketamine (CeK) set (at anesthesiologist's discretion) at 0.1 ug/ml for at least 30 minute and BIS during a propofol-remifentanil general anesthesia will be correlated.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CeK 0.2</arm_group_label>
    <description>Data about Continuous infusion with Concentration at the effector site of Ketamine (CeK) set (at anesthesiologist's discretion) at 0.2 ug/ml for at least 30 minute and BIS during a propofol-remifentanil general anesthesia will be correlated.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CeK 0.4</arm_group_label>
    <description>Data about Continuous infusion with Concentration at the effector site of Ketamine (CeK) set (at anesthesiologist's discretion) at 0.4 ug/ml for at least 30 minute and BIS during a propofol-remifentanil general anesthesia will be correlated.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CeK 0.6</arm_group_label>
    <description>Data about Continuous infusion with Concentration at the effector site of Ketamine (CeK) set (at anesthesiologist's discretion) at 0.1 ug/ml for at least 30 minute and BIS during a propofol-remifentanil general anesthesia will be correlated.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>CeK will be set at anesthesiologist's discretion. Only patients with continuous infusion of CeK 0.1, 0.2, 0.4 or 0.6 for at least 30 minutes will be considered.</description>
    <arm_group_label>CeK 0.1</arm_group_label>
    <arm_group_label>CeK 0.2</arm_group_label>
    <arm_group_label>CeK 0.4</arm_group_label>
    <arm_group_label>CeK 0.6</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Authors will recruit patients who will undergo breast oncologic surgery and anesthetized&#xD;
        with TIVA-TCI propofol,remifentanil and ketamine anesthesia.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Undergo general anaesthesia with Targeted Controlled Infusion of Ketamine (Domino&#xD;
             model), Propofol (Schnider model) and Remifentanil (Minto model)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Neurological disease&#xD;
&#xD;
          -  Psychiatric disease&#xD;
&#xD;
          -  Benzodiazepines intake&#xD;
&#xD;
          -  Obesity&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
  </eligibility>
  <verification_date>April 2023</verification_date>
  <study_first_submitted>March 22, 2023</study_first_submitted>
  <study_first_submitted_qc>April 3, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2023</study_first_posted>
  <last_update_submitted>April 3, 2023</last_update_submitted>
  <last_update_submitted_qc>April 3, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Padova</investigator_affiliation>
    <investigator_full_name>Federico Linassi</investigator_full_name>
    <investigator_title>MD, Principal investigator</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

